2-(M-tolyl)cyclopropan-1-amine | 1157139-71-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(M-tolyl)cyclopropan-1-amine
• 英文别名: 2-(3-methylphenyl)cyclopropan-1-amine
• CAS: 1157139-71-3
• 化学式: C₁₀H₁₃N
• 分子量: 147.22
• InChiKey: RYKBYDBWVDJQET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(M-tolyl)cyclopropan-1-amine 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Extended N6 substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor

  摘要：

  2-Arylethynyl-(N)-methanocarba adenosine 5'-methyluronamides containing rigid N-6-(trans-2-phenylcyclopropyl) and 2-phenylethynyl groups were synthesized as agonists for probing structural features of the A(3) adenosine receptor (AR). Radioligand binding confirmed A(3)AR selectivity and N-6-1S,2R stereoselectivity for one diastereomeric pair. The environment of receptor-bound, conformationally constrained N-6 groups was explored by docking to an A(3)AR homology model, indicating specific hydrophobic interactions with the second extracellular loop able to modulate the affinity profile. 2-Pyridylethynyl derivative 18 was administered orally in mice to reduce chronic neuropathic pain in the chronic constriction injury model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2014.06.006

文献信息

• [EN] A3 ADENOSINE RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE A3
  申请人：US HEALTH

  公开号：WO2015080940A1

  公开（公告）日：2015-06-04

  Disclosed are compounds of the formula (I) and (II) which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.

  揭示了公式(I)和(II)的化合物，这些化合物是A3腺苷受体激动剂，包括这些化合物的药物组合物，以及使用这些化合物的方法，其中X、Y、Z、R2-R6和R103-R106如规范中所定义。这些化合物对A3受体具有选择性，可用于治疗或预防多种疾病或症状，例如神经病性疼痛。
• Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability
  申请人：Silverman Richard B.

  公开号：US20100190230A1

  公开（公告）日：2010-07-29

  Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases.

  化合物和相关组合物以及用于抑制神经元一氧化氮合酶并可用于治疗各种神经退行性疾病的方法。
• TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS
  申请人：AstraZeneca AB

  公开号：EP0996621B1

  公开（公告）日：2003-10-01
• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property (No. 2) Limited

  公开号：EP2688568B1

  公开（公告）日：2019-06-19
• CYCLOPROPANAMINE COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2907802B1

  公开（公告）日：2019-08-07